brain cell News
-
TechOhio: This Cincinnati Startup is Creating a Non-Invasive Way to Diagnose and Monitor Stroke and Brain Injuries.
When someone suffers a stroke, time to proper care is critical. As Sense Neuro CTO and medical co-founder George Shaw, MD tells TechOhio, “not all hospitals are comprehensive stroke centers where they have the techniques to treat different types of strokes. You might be taken to the wrong hospital if EMS can’t determine what kind of stroke it is. If you need to be transferred from one ...
-
Cyborg Brains Play Pong in the Matrix
A team of scientists in Australia has taught a petri dish of brain cells to play Pong. According to an article from Input Magazine, “As Brett Kagan, chief scientific officer of Cortical Labs explains, these neurons are more than just a dumping of brain cells on a dish. They’re a network capable of learning and completing tasks. ‘We often refer to them as living in the ...
By ni2o, Inc.
-
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
NESS ZIONA, ISRAEL, December 12, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the Israel Innovation Authority (IIA).This brings the total amount of financing raised by Kadimastem in 2021 to ...
-
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
-
Made in Quebec: Illuminating hidden brain cancer cells
It’s a scene that plays out daily in operating rooms around the world: a surgeon removes a malignant brain tumour. But rather than registering the satisfaction of having saved a patient’s life, hanging in the air is an all-too-real statistic; in 99.5% of these operations, unseen cancer cells remain. That hidden cancer will eventually grow and spread, and the operation will have become ...
-
Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation ...
By Neurolutions
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
An Overview of Glioblastoma
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV ...
-
Agilent Technologies and Daegu Gyeongbuk Institute of Science and Technology Collaborate on Neurometabolomics Research
Agilent Technologies Inc. (NYSE: A) and the Daegu Gyeongbuk Institute of Science and Technology today announced a strategic collaboration with the opening of the DGIST's new Neurometabolomics Excellence Research Center. The center will use Agilent's bio-analytical instruments in its neurometabolomics research of biomarkers for early detection and diagnosis of brain diseases. DGIST is one of ...
-
Why Sleep Deprivation Is a Serious Threat to Firefighters
Serving in the line of duty results in an abundance of health risks for firefighters, though perhaps none more silent or threatening than the constant onslaught of sleep deprivation. David F. Peterson, a retired fire chief and current fire training coordinator of Blackhawk Technical College in Janesville, Wisc., has made it his mission to expose the ongoing dangers of sleep deprivation and ...
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
Translating great stem cell ideas into effective therapies
In science, there are a lot of terms that could easily mystify people without a research background; “translational” is not one of them. Translational research simply means to take findings from basic research and advance them into something that is ready to be tested in people in a clinical trial. Yesterday our Governing Board approved $15 million in funding for four projects as ...
-
Alzheimer’s Drug Discovery Foundation’s diagnostics accelerator announces first digital biomarker research award and data sharing platform
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
-
Saneron and Henry Ford Health: Cell Therapy Combo Aids Stroke
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells (HUCBCs) were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs. The study was published in a recent issue of ...
-
Lauren Sciences awarded grant by Voices Against Brain Cancer to develop V-Smart Nanomedicine for GBM
New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should ...
-
Metlife foundation announces major awards to scientists for research in alzheimer`s disease
The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, Ph.D., professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute Investigator, and Marcus E. Raichle, M.D., professor of radiology and neurology at Washington University ...
-
Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma ...
-
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...
By Bayer AG
-
Woolsey Pharmaceuticals Begins ALS Study
NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as ...
-
Stem Pharm Awarded $1.7M NIH SBIR Grant for Better Models of the Brain
Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH) to optimize its induced pluripotent stem cell (iPSC)-derived model of the central nervous system for drug discovery and toxicology applications. Stem Pharm’s model fills a commercial need to accurately reflect the complexity of cell ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you